Samsung Bioepis Co., Ltd.
- Country
- 🇰🇷South Korea
- Ownership
- Subsidiary
- Established
- 2012-01-01
- Employees
- 501
- Market Cap
- -
A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria
- Conditions
- Interventions
- First Posted Date
- 2019-08-15
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04058158
- Locations
- 🇮🇳
Fortis Memorial Research Institute, Gurgaon, Haryana, India
🇲🇾Hospital Sultanah Aminah, Johor Bahru, Malaysia
🇲🇾Hospital Pulau Pinang, Pulau Pinang, Malaysia
Pharmacokinetic, Safety, Tolerability, Immunogenicity, and Pharmacodynamic Study of SB12 in Healthy Subjects
- First Posted Date
- 2018-10-26
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT03722329
- Locations
- 🇩🇪
PAREXEL International GmbH, Early Phase Clinical Unit - Berlin, Berlin, Germany
A Phase I Study of SB26 in Healthy Volunteers
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT03630627
- Locations
- 🇺🇸
PAREXEL International, Glendale, California, United States
An Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in Subjects With Rheumatoid Arthritis
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT03193957
- Locations
- 🇵🇱
AI Centrum Medyczne, Poznań, Poland
Pharmacokinetics, Safety, and Tolerability Study of the Autoinjector and Pre-filled Syringe of SB4 in Healthy Male Subjects
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2017-09-28
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT03193203
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)
- Conditions
- Interventions
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2021-05-21
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 705
- Registration Number
- NCT03150589
- Locations
- 🇺🇸
Southeast Retina Center, Augusta, Georgia, United States
🇺🇸Retina Vitreous Surgeons fo Central NY, PC, Syracuse, New York, United States
🇺🇸Charleston Neuroscience Institute, Ladson, South Carolina, United States
A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC
- Conditions
- Interventions
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 538
- Registration Number
- NCT02771795
- Locations
- 🇷🇺
BHI of Omsk Region "Clinical Oncology Dispensary", Оmsk, Russian Federation
🇧🇬Complex Oncological Center - Vratsa, EOOD, Vratsa, Bulgaria
🇫🇷CHU Besançon - Hôpital Jean Minjoz, Besançon, France
A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 763
- Registration Number
- NCT02754882
- Locations
- 🇨🇳
E-Da Hospital, Kaohsiung, Taiwan
🇧🇾Brest Regional Oncology Dispensary, Brest, Belarus
🇬🇪LTD Research Institute of Clinical Medicine, Tbilisi, Georgia
An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 49
- Registration Number
- NCT02565810
- Locations
- 🇵🇱
Medica pro Familia Sp z o.o. S.K.A Oddzial Warszawa, Warszawa, Poland
🇵🇱Medica Pro Familia Sp. z o.o. S.K.A. Oddzial Gdynia, Gdynia, Poland
Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2019-06-03
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 119
- Registration Number
- NCT02453672
- Locations
- 🇧🇪
Samsung Investigational Site, Antwerp, Belgium